In this Issue
- Psychedelics Insiders Draw Up Trump 2.0 Wishlist
- Rick Doblin Reflects on Lykos’ Strategy as MAPS Settles with FDA
- Polish Medical Research Agency Set to Provide PLN 16M ($4M) to Psilocybin Study
- VA Issues Note on Psychedelics for PTSD; Officially Funds Psychedelics Study
- Alleged Killer of UnitedHealth CEO Apparently Interested in Psychedelics
- Other Stories including: MDMA Plus Massed Exposure Therapy Protocol Published; Pollan Pushes Back on RFK Jr. Hype; Greenbrook TMS Stock Slumps Following Q3 Earnings; 30 Magic Mushroom Hops Shutter in Ontario; Expression of Concern Issued Over MAPS/Lykos Journal Article; Relmada Therapeutics’ Phase 3 MDD Drug Fails; and more…
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue